8-K: Cartesian Therapeutics Initiates Pivotal Phase 3 Trial for Lead Autoimmune Cell Therapy Descartes-08 in Myasthenia Gravis

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, a CAR-T cell therapy targeting myasthenia gravis, marking a significant advancement in its clinical development.

Summary

• Cartesian Therapeutics, Inc. (NASDAQ: RNAC) has enrolled the first participant in its Phase 3 AURORA trial for Descartes-08 in patients with myasthenia gravis (MG).
• Descartes-08 is the company's lead autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) candidate, designed to target B-cell maturation antigen (BCMA).
• The therapy is intended for outpatient administration without the need for preconditioning chemotherapy and does not use integrating vectors.
• The Phase 3 AURORA trial is a 1:1 randomized study comparing Descartes-08 to placebo in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG.
• Participants will receive six once-weekly outpatient infusions.
• The primary endpoint for the trial is the proportion of Descartes-08 participants achieving an improvement of three points or more in their MG Activities of Daily Living (MG-ADL) score at Month 4 compared to placebo.
• Updated efficacy and safety data from the Phase 2b trial of Descartes-08 in MG, announced in April 2025, showed sustained deep responses through 12 months after a single course of therapy.
• In the Phase 2b trial, Descartes-08-treated participants observed an average 4.8-point reduction in the MG-ADL score at Month 12.
• For participants without prior exposure to biologic therapies in the Phase 2b trial, an average 7.1-point reduction in MG-ADL was observed, with 57% maintaining minimum symptom expression at Month 12.
• The safety profile of Descartes-08 in the Phase 2b trial was consistent with previous data and supports outpatient administration.
• Cartesian's pipeline also includes Descartes-15, a next-generation anti-BCMA CAR-T in Phase 1 for multiple myeloma, and Descartes-08 is also in Phase 2 development for systemic lupus erythematosus with a planned Phase 2 basket trial for other autoimmune indications.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant advancement of the lead therapeutic candidate, Descartes-08, into a pivotal Phase 3 trial for myasthenia gravis. This milestone, coupled with strong positive data from the preceding Phase 2b trial and the innovative outpatient administration approach, indicates strong progress and potential for the company.

Positives

• Enrollment of the first participant in the pivotal Phase 3 AURORA trial represents a significant clinical development milestone for Descartes-08.
• Descartes-08 is designed for outpatient administration without preconditioning chemotherapy, potentially offering a more convenient and safer treatment option.
• Phase 2b trial results demonstrated sustained deep responses through 12 months with a single course of therapy, including an average 4.8-point reduction in MG-ADL score at Month 12.
• Particularly strong results were observed in biologic-naive patients in Phase 2b, with an average 7.1-point MG-ADL reduction and 57% achieving minimum symptom expression at Month 12.
• The consistent safety profile of Descartes-08 supports its outpatient use, which is a key differentiator.
• The company is pioneering cell therapy for autoimmune diseases, addressing a significant unmet medical need.

Risks

• The uncertainties inherent in the initiation, completion, and cost of clinical trials, including uncertain outcomes.
• The availability and timing of data from ongoing and future clinical trials and the results of such trials.
• Whether preliminary results from a particular clinical trial will be predictive of the final results of that trial.
• Whether results of early clinical trials will be indicative of the results of later clinical trials.
• Whether results observed in certain patient subgroups will be indicative of the results in such subgroups in later clinical trials or are reflective of a product candidate's overall characteristics.
• The ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects.
• The unproven approach of the company's technology.
• Potential delays in enrollment of patients.
• Undesirable side effects of the company's product candidates.
• Reliance on third parties to conduct clinical trials.
• Inability to maintain existing or future collaborations, licenses, or contractual relationships.
• Inability to protect proprietary technology and intellectual property.
• Potential delays in regulatory approvals.
• Availability of funding sufficient for foreseeable and unforeseeable operating expenses and capital expenditure requirements.
• Recurring losses from operations and negative cash flows.
• Substantial fluctuation in the price of the company's common stock.
• Risks related to geopolitical conflicts and pandemics.

Future Outlook

Cartesian Therapeutics anticipates that Descartes-08 has the potential to transform the current myasthenia gravis treatment paradigm by offering a differentiated, durable treatment option with just a single course of therapy, administered without preconditioning chemotherapy in an outpatient setting. The company aims to advance this important study and potentially fulfill unmet medical needs in autoimmune diseases.

Management Comments

• Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian, stated: 'Commencement of our Phase 3 AURORA trial represents a significant milestone in our mission to deliver a differentiated, durable treatment option to patients with MG. With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy.'
• James (Chip) F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine, commented: 'Marked by chronic use of steroids and other immunosuppressants while often delivering only limited efficacy, the current standard of care for patients with MG is inadequate. Supported by compelling results from the Phase 2b trial, I firmly believe that Descartes-08 has the potential to serve as a safe, flexible, and durable treatment option for patients with MG. I look forward to helping advance this important study.'

Industry Context

This announcement positions Cartesian Therapeutics at the forefront of developing novel cell therapies for autoimmune diseases, a field with significant unmet medical needs where current standards of care often involve chronic immunosuppression with limited efficacy. The advancement of a CAR-T therapy for an autoimmune indication like myasthenia gravis, especially one designed for outpatient administration without preconditioning, represents a potentially disruptive innovation in the biotechnology and pharmaceutical industry, moving beyond oncology applications for CAR-T.

Stakeholder Impact

• **Shareholders:** Positive impact due to the advancement of the company's lead asset into a pivotal Phase 3 trial, which is a significant value-driving milestone for a biotech company.
• **Patients with Myasthenia Gravis:** Potential for a new, more convenient, and durable treatment option that could transform the current standard of care, especially for those who have not responded well to existing therapies.
• **Healthcare Providers:** Potential for a novel CAR-T therapy that can be administered in an outpatient setting without preconditioning chemotherapy, simplifying treatment protocols.
• **Employees:** Positive impact from the company's progress in clinical development, potentially leading to increased job security and opportunities.

Next Steps

• Continue enrollment and conduct of the Phase 3 AURORA trial for Descartes-08 in patients with myasthenia gravis.
• Further development of Descartes-08 for systemic lupus erythematosus and other autoimmune indications in planned Phase 2 trials.
• Continued evaluation of Descartes-15 in its Phase 1 trial for multiple myeloma.

Key Dates

Recommendation

Keywords

Cartesian Therapeutics, Descartes-08, Myasthenia Gravis, CAR-T cell therapy, Autoimmune disease, Phase 3 clinical trial, AURORA trial, BCMA, Clinical-stage biotechnology, Outpatient therapy, Immunosuppressants, Systemic lupus erythematosus, Multiple myeloma